Cargando…
Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence
PURPOSE: To investigate clinical management of primary open-angle glaucoma (POAG) in the United States using real-world evidence and to examine healthcare resource utilization (HCRU), medication adherence/persistence, and procedure use. DESIGN: A cross-sectional, retrospective analysis of Optum’s de...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394656/ https://www.ncbi.nlm.nih.gov/pubmed/36003802 http://dx.doi.org/10.2147/PPA.S367443 |
_version_ | 1784771526268026880 |
---|---|
author | Imperato, Joseph S Zou, Kelly H Li, Jim Z Hassan, Tarek A |
author_facet | Imperato, Joseph S Zou, Kelly H Li, Jim Z Hassan, Tarek A |
author_sort | Imperato, Joseph S |
collection | PubMed |
description | PURPOSE: To investigate clinical management of primary open-angle glaucoma (POAG) in the United States using real-world evidence and to examine healthcare resource utilization (HCRU), medication adherence/persistence, and procedure use. DESIGN: A cross-sectional, retrospective analysis of Optum’s de-identified Market Clarity Dataset (July 1, 2013–December 31, 2019). PATIENTS AND METHODS: Patients ≥18 years with POAG diagnosis and continuous enrollment for 1-year pre- and post-index were eligible and categorized into four mutually exclusive cohorts: CH1, treated with antiglaucoma medication(s) only; CH2, underwent glaucoma procedure(s) only; CH3, treated with antiglaucoma medication(s) and underwent procedure(s); and CH4, received no treatment for POAG. Adherence and persistence with antiglaucoma medications, and disease-specific HCRU were analyzed. Pairwise two-sample comparisons and multivariate regressions were conducted. RESULTS: Examined 232,572 eligible patients (CH1=60,895; CH2=4330; CH3=6027; CH4=161,320). Prostaglandin analogs were most prescribed antiglaucoma medications (CH1: 69.7%; CH3: 62.7%), of which latanoprost was most common (CH1: 51.3%; CH3: 46.1%). Disease-specific office visits occurred in 26.3%, 78.2%, 75.0%, 23.8%, and surgical services visits occurred in 3.8%, 36.3%, 42.5%, 3.3%, in CH1-CH4, respectively. Adherence was higher (medication possession ratio: 47.1% vs 39.4%; P<0.0001), and more patients remained persistent across 1-year post-index period in CH1 vs CH3 (25.4% vs 16.1%; P<0.0001). Positive predictors of medication persistence included being female, ≥55 years, and history of dyslipidemia or thyroid disease (all P≤0.0003). CONCLUSION: Overall, 70% POAG patients might not have received antiglaucoma treatment. Since POAG is a slowly progressive blinding disease, the lack of antiglaucoma treatment and suboptimal adherence/persistence with medications are of major concerns. Targeted screening and educational approaches are needed to improve POAG management. |
format | Online Article Text |
id | pubmed-9394656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93946562022-08-23 Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence Imperato, Joseph S Zou, Kelly H Li, Jim Z Hassan, Tarek A Patient Prefer Adherence Original Research PURPOSE: To investigate clinical management of primary open-angle glaucoma (POAG) in the United States using real-world evidence and to examine healthcare resource utilization (HCRU), medication adherence/persistence, and procedure use. DESIGN: A cross-sectional, retrospective analysis of Optum’s de-identified Market Clarity Dataset (July 1, 2013–December 31, 2019). PATIENTS AND METHODS: Patients ≥18 years with POAG diagnosis and continuous enrollment for 1-year pre- and post-index were eligible and categorized into four mutually exclusive cohorts: CH1, treated with antiglaucoma medication(s) only; CH2, underwent glaucoma procedure(s) only; CH3, treated with antiglaucoma medication(s) and underwent procedure(s); and CH4, received no treatment for POAG. Adherence and persistence with antiglaucoma medications, and disease-specific HCRU were analyzed. Pairwise two-sample comparisons and multivariate regressions were conducted. RESULTS: Examined 232,572 eligible patients (CH1=60,895; CH2=4330; CH3=6027; CH4=161,320). Prostaglandin analogs were most prescribed antiglaucoma medications (CH1: 69.7%; CH3: 62.7%), of which latanoprost was most common (CH1: 51.3%; CH3: 46.1%). Disease-specific office visits occurred in 26.3%, 78.2%, 75.0%, 23.8%, and surgical services visits occurred in 3.8%, 36.3%, 42.5%, 3.3%, in CH1-CH4, respectively. Adherence was higher (medication possession ratio: 47.1% vs 39.4%; P<0.0001), and more patients remained persistent across 1-year post-index period in CH1 vs CH3 (25.4% vs 16.1%; P<0.0001). Positive predictors of medication persistence included being female, ≥55 years, and history of dyslipidemia or thyroid disease (all P≤0.0003). CONCLUSION: Overall, 70% POAG patients might not have received antiglaucoma treatment. Since POAG is a slowly progressive blinding disease, the lack of antiglaucoma treatment and suboptimal adherence/persistence with medications are of major concerns. Targeted screening and educational approaches are needed to improve POAG management. Dove 2022-08-18 /pmc/articles/PMC9394656/ /pubmed/36003802 http://dx.doi.org/10.2147/PPA.S367443 Text en © 2022 Imperato et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Imperato, Joseph S Zou, Kelly H Li, Jim Z Hassan, Tarek A Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title | Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title_full | Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title_fullStr | Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title_full_unstemmed | Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title_short | Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence |
title_sort | clinical practice management of primary open-angle glaucoma in the united states: an analysis of real-world evidence |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394656/ https://www.ncbi.nlm.nih.gov/pubmed/36003802 http://dx.doi.org/10.2147/PPA.S367443 |
work_keys_str_mv | AT imperatojosephs clinicalpracticemanagementofprimaryopenangleglaucomaintheunitedstatesananalysisofrealworldevidence AT zoukellyh clinicalpracticemanagementofprimaryopenangleglaucomaintheunitedstatesananalysisofrealworldevidence AT lijimz clinicalpracticemanagementofprimaryopenangleglaucomaintheunitedstatesananalysisofrealworldevidence AT hassantareka clinicalpracticemanagementofprimaryopenangleglaucomaintheunitedstatesananalysisofrealworldevidence |